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Prophylactic hyperthermic 
intraperitoneal chemotherapy in 
gastric cancer management: short- and 
long-term outcomes of a prospective 
randomized study
ABSTRACT
Introduction. Assessment of toxicity and long-term results of hyperthermic intraperitoneal chemotherapy (HIPEC) 
treatment administered to patients with resectable serosa-invasive gastric cancers. 
Material and methods. The study was carried out in 2008–2016 and is based on the results of the treatment of 154 gastric 
cancer patients (stage IIB–IIIC, III–IV Borrmann type) who were randomly assigned to two groups. 76 patients underwent 
HIPEC combined with radical gastrectomy (HIPEC group) and 78 patients underwent radical gastrectomy without HIPEC 
(control group). HIPEC was administered after alimentary tract reconstruction and wound closure and comprised 5–6 L 
of Ringer’s solution (cisplatin 50 mg/m2 + doxorubicin 50 mg/m2) infused at an inflow temperature of 42°C for 1 hour. 
Results. Although the total number of complications was higher in the HIPEC group than in the control group the 
difference was statistically insignificant — 20 (26.3%) and 12 (15.3%), respectively (p = 0.141). Surgery-related com-
plications in the HIPEC and control groups were observed in 9 and 5 cases, respectively (p = 0.372). Non-surgical 
complications were recorded in 11 and 7 cases, respectively (p = 0.435). Overall, the proposed HIPEC regimen 
administered in combination with radical surgery demonstrated satisfactory patient tolerability. The frequency of 
grade III toxic reactions according to CTCAE version 5.0 was 9.2%, no grade IV–V toxicities were registered at that. 
These satisfactory short-term results were followed up with fairly good long-term treatment outcomes. There was 
an increase in 5-year progression-free survival (42.1 ± 6.3% vs. 16.3 ± 5.5%, p < 0.001) and in dissemination-free 
survival (45.2 ± 6.3% vs. 19.4 ± 5.9%, p = 0.001) in the HIPEC group vs. the control group with a trend toward 
improving cancer-specific survival (CSS) in the HIPEC-treated patients [45.1.0 ± 6.4% vs. 27.0 ± 6.7% (p = 0.050)]. 
Conclusion. While substantially improving long-term GC therapeutic effect, the proposed HIPEC regimen using 
cisplatin 50 mg/m2 in combination with doxorubicin 50 mg/m2 made it possible to minimize complications (fre-
quency of 26.3%) and toxic reactions [the frequency of grade III toxic reactions was 9.2% (CTCAE, version 5.0)].
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The present report focuses on analyzing and system-
izing short- and longer-term outcomes of managing radi-
cal surgery/hyperthermic intraperitoneal chemotherapy 
(HIPEC) treated patients in the context of observed 
post-HIPEC toxicity in patients. Being a follow-up to 
our previous publications [1, 2] that dealt with long-term 
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preventive efficacy assessment of HIPEC with regard 
to the peritoneal recurrence of gastric carcinoma in 
patients, this report is likewise based on the outcomes 
of our randomized study undertaken at the National 
Cancer Center of Belarus in 2008–2016. The present 
report incorporates the study’s underlying assump-
tions, principles and methodology and includes its main 
statistical data and descriptive information for the sake 
of ensuring coherence in the presentation of research 
results. 
The trial was approved by the Ethics Committee of 
the N.N. Alexandrov National Center, and a written 
informed consent was obtained from all the patients.
Material and methods 
Patients
As we reported previously [2], the study involved pa-
tients with histologically confirmed gastric cancer, aged 
18–70, T4a-bN0-3M0, stage IIB–IIIC, with preoperative 
ECOG status of 0–I, without esophagus involvement, 
who underwent a potentially curative operation (i.e. 
R0 resection). Resectable serosa-invasive gastric cancer 
patients were included in the study only after intraopera-
tively obtaining morphological confirmation of serosal 
invasion (pT4) by employing a frozen section procedure. 
Borrmann type III–IV was used as an inclusion criterion. 
Resectability was established according to the results of 
a pre-operative CT and ultrasonographic examination. 
Surgical treatment consisted of total or partial (dis-
tal subtotal resection) gastrectomy with free margins 
(R0 resection) and D2 lymph node dissection, in case 
of necessity supplemented by liver, distal pancreatic or 
transverse colon resections.
HIPEC regimen
HIPEC was performed after gastrectomy/alimentary 
tract reconstruction and wound closure. One inflow 
catheter (30F) was positioned beneath the left hemidi-
aphragm. Three outflow catheters (32F) were placed 
in both the true and false pelvises in the subhepatic 
area. Temperature probes were placed on the inflow 
and outflow catheter tips. HIPEC was administered for 
one hour with an automatic HIPEC device. Perfusate 
used was Ringer’s solution (5–6 L) mixed with cisplatin 
50 mg/m2 + doxorubicin 50 mg/m2 warmed to an inflow 
temperature of 42°C. Since the study was launched in 
2008, i.e. prior to accepting perioperative chemotherapy 
as a standard requirement in GC management, none of 
the patients in the study was administered periopera-
tive chemotherapy.
The severity of HIPEC-related side effects was 
measured using the CTCAE grading scale, v5.0 (https://
ctep.cancer.gov/protocoldevelopment/electronic_ap-
plications/docs/ctcae_v5_ quick_reference_5x7.pdf).
As was previously reported [2], progression-free 
survival (PFS) was the primary endpoint of the study. 
PFS was measured from the date of random assignment 
to the date of gastric cancer progression. Secondary 
endpoints included dissemination-free survival (DFS), 
measured from the date of random assignment to the 
date of gastric cancer progression with metachronous 
peritoneal metastases, cancer-specific survival (CSS), 
measured from the date of random assignment to the 
date of death from the same cancer, and overall survival 
(OS), measured from the date of random assignment 
to the date of death from any cause. All same cancer 
recurrences (metachronous peritoneal metastases, dis-
tant metastases) and deaths from the same cancer were 
accounted for as events.
Statistical analysis
Descriptive analysis variables were expressed as 
mean ± standard deviation (SD) or counts and per-
centages [n (%)], as appropriate. Also used for groups’ 
comparison were t-test, Chi-square test, and Fisher’s 
exact test, if assumptions of Chi-square test were 
violated. The survival rate was assessed applying the 
Kaplan-Meier estimator. Multivariate Cox model was 
used to determine PFS risk factors. Hazard ratios (HRs) 
and their 95% confidence intervals (CIs) were calculated 
using an exponential transformation of the respective 
parameters of the models.
Statistical analysis of the data was performed using 
the R version 3.1.1 statistical software (GPL license) [3].
Results
Patient characteristics
As we mentioned previously [2], between 2008 and 
2016 a total of 478 patients gave their consent to par-
ticipate in the trial. However, as the trial progressed, 
27 patients withdrew their consent to participate, 
281 patients were excluded as not intraoperatively 
confirmed to have serosal invasion (pT2N0-3M0; 
pT3N0-3M0), and 16 patients were excluded due to 
the presence of co-morbidities that led to the reduc-
tion of the volume of lymph node dissection to D1. 
As a result, the trial included 154 patients with gastric 
cancer [stage IIB–IIIC (T4a-bN0-3M0), III–IV Bor-
rmann type], without esophagus involvement, who 
underwent a potentially curative operation (i.e. R0 re-
section), and who were randomized after intraoperative 
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Table 1. Patient characteristics
Variable HIPEC group, 
n = 68 (%)
Control group, 











56 ± 8 56 ± 9 0.75
pT 0.46
pT4a 55 (80.9) 48 (87.3)
pT4b 13 (19.1) 7 (12.7)
pN 0.76
pN0 23 (33.8) 14 (25.5)
pN1 8 (11.8) 6 (10.9)
pN2 15 (22.1) 14 (25.5)
pN3 22 (32.4) 21 (38.2)
G 0.14
GI 6 (8.8) 4 (7.3)
GII 17 (25.0) 9 (16.4)
GIII 39 (57.4) 29 (52.7)
GIV 6 (8.8) 13 (23.6)
SD — standard deviation
Table 2. Postoperative morbidity (surgical complications)
Type of complications n (%) CTCAE  
v 5.0 grade
HIPEC group 
Postoperative pancreatitis 4 (44.4%) II
Pancreatic fistula 1 (11.1%) II
Volvulus of ileal loops, serosal 
peritonitis
1 (11.1%) IV






Wound infection 2 (40.0%) II
Postoperative pancreatitis 2 (40.0%) II




HIPEC — hyperthermic intraperitoneal chemotherapy
morphological confirmation of serosal invasion (pT4) 
based on frozen section procedure. The evaluation of 
toxicities and surgical complications was based on the 
results of treating the aforesaid 154 patients including 
76 patients in the HIPEC group (male/female — 50/26) 
and 78 patients in the control group (male/female 
— 45/33). The assessment of long-term treatment 
results included 123 patients whose data were avail-
able for analysis. Excluded from this analysis as not 
meeting the study inclusion criteria were 8 patients 
from the HIPEC group (R1 resection — 2 patients, 
unconfirmed gastric cancer — 1 patient, Borrmann 
type I–II — 5 patients) and 23 patients from the control 
group (R1 resection — 2 patients, unconfirmed gastric 
cancer — 1 patient, Borrmann type I–II — 14 patients, 
refused to participate in the study — 3 patients, early 
withdrawal, no data available — 3 patients). The two 
groups were well balanced (Tab. 1).
Complications
Complications were observed in 13 patients in the 
HIPEC group and in 11 patients in the control group 
with 2 or more complications diagnosed in 5 patients in 
the HIPEC group and in 1 patient in the control group. 
Although the total number of complications in the HI-
PEC group was higher than in the control group it was 
statistically insignificant — 20 (26.3%) and 12 (15.3%), 
respectively (p = 0.141). Surgery-related complica-
tions in the HIPEC and control groups were observed 
in 9 and 5 cases, respectively (p = 0.372) (Tab. 2), 
non-surgical complications — in 11 and 7 cases, respec-
tively (p = 0.435) (Tab. 3). 
Hematological toxicity was the most frequently reg-
istered side-effect reaction. However, no grade IV–V 
toxic reactions were observed, while grade III toxicities 
were basically of hematological origin and did not exceed 
9.2% (7 patients). That puts our study at an advantage 
compared with earlier reported trials [7–10] (Tab. 4). 
Another positive outcome of the proposed HIPEC 
regimen was survival rate improvements compared 
with surgery-only GC treatment. There was a statisti-
cally significant increase in 5-year progression-free 
(42.1 ± 6.3% vs. 16.3 ± 5.5%, p < 0.001) and 
dissemination-free (45.2 ± 6.3% vs. 19.4 ± 5.9%, 
p = 0.001) survivals in the HIPEC group with a trend 
toward improving cancer-specific survival (CSS) in the 
HIPEC-treated patients [45.1.0 ± 6.4% vs. 27.0 ± 6.7% 
(p = 0.050)] (Fig. 1–3).
The effect of the proposed combined HIPEC/surgery 
treatment on prognosticating GC progression risks was 
measured by means of a regression analysis based on 
the Cox proportional hazards model. Covariates used in 
the model included HIPEC proper, the state of regional 
lymph node (pN0, pN1-2, pN3), and performed surgical 
procedure. The model did not include universally known 
factors of adverse prognostication used as inclusion crite-
ria in the present study (macroscopic growth form – stage 
III–IV in the Bormann classification, serosal invasion by 
tumor or tumor invasion of adjacent structures – pT4a–b, 
and D2 lymph node dissection) (Tab. 5).
4
ONCOLOGY IN CLINICAL PRACTICE 2021, Vol. 17, No. 4
Table 3. Postoperative morbidity (non-surgical complications)
Type of complications n (%) CTCAE 
v 5.0 grade
HIPEC group 
Enterocolitis 1 (9.1%) I
Fever of unclear genesis 2 (18.1%) I
Pneumonia 5 (45.5%) II




Acute kidney failure 1 (9.1%) II
Total: 11 (100%)
Control group 
Pneumonia 4 (57.1%) II
Myocardial infarction 1 (14.3%) II
Acute ischemic stroke 1 (14.3%) V




HIPEC — hyperthermic intraperitoneal chemotherapy
Table 4. Toxicity profile of HIPEC-treated patients (CTCAE, v 5.0)
Event Degree of toxicity, n, %
I II III IV V
Gastrointestinal toxicity
Nausea 18 (23.7%) 4 (5.3%) – – –
Vomiting 4 (5.3%) 3 (3.9%) – – –
Diarrhea 4 (5.3%) 2 (2.6%) – – –
Hematological toxicity
Anemia 20 (26.3%) 9 (11.8%) 1 (1.3%) – –
Lymphocyte count decreased 35 (46.1%) 19 (25%) 6 (7.9%) – –
Neutrophil count decreased 1 (1.3%) – – – –
Thrombocytopenia – – – – –
Metabolic Toxicity
Aspartate aminotransferase 31 (40.8%) 3 (3.9%) – – –
Alanine aminotransferase 24 (31.6%) 4 (5.3%) – – –
Blood bilirubin increased 2 (2.6%) 3 (3.9%) – – –
Creatinine increased 2 (2.6%) 3 (3.9%) – – –
Constitutional symptoms 2 (2.6%) 2 (2.6%) – – –
As we reported earlier [2] our multivariate Cox 
model analysis showed an increased risk of disease 
progression in (a) cases of regional lymph node me-
tastases; (b) cases requiring gastrectomy or combined 
gastrectomy; and (c) the control group. The analysis 

























Figure 1. Cancer-specific survival in the HIPEC and control 
groups; HIPEC — hyperthermic intraperitoneal chemotherapy
Figure 2. Progression-free survival in the HIPEC and control 
groups; HIPEC — hyperthermic intraperitoneal chemotherapy
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Table 5. Factors associated with gastric cancer progression 
(Cox model)
Variables b HR (95% CI) p
pN1–2 vs. pN0 0.88 2.4 (1.3–4.6) 0.008
pN3 vs. pN0 1.51 4.5 (2.4–8.6) < 0.001
Gastrectomy + combined 
gastrectomy
vs. subtotal gastric resection
0.63 1.9 (1.1–3.1) 0.013
Surgery vs. surgery + HIPEC 0.7 2.0 (1.3–3.0) 0.003














Figure 3. Dissemination-free survival in the HIPEC and 
control groups; HIPEC — hyperthermic intraperitoneal 
chemotherapy
in the absence of HIPEC treatment and highlighted 
the importance of this adjuvant treatment mode in the 
management of radically operated GC patients.
Discussion
The data presented above are consistent with the 
findings of some authors [4–6], who also observed no 
difference in the number of postoperative complications 
between the HIPEC/surgery group of patients and the 
surgery-only group of patients. For example, Kim and 
Bae (2001) [4] reported that the number of postopera-
tive complications in the patients of the HIPEC and 
control groups was 36.5% and 33.3%, respectively. 
In our study these figures were 25.6% and 15.4%, re-
spectively. Also, compared with similar published studies 
[7–10], a noteworthy outcome of the proposed HIPEC 
regimen was the absence of grade IV–V toxic reactions. 
Chemo-tolerability in the overall evaluation of the 
efficacy of any chemotherapy regimen is a no less im-
portant factor ensuring adequate quality of life than im-
provements in long-term GC treatment outcomes [11]. 
Since the first trials of HIPEC prophylactic treat-
ment of peritoneal recurrence after GC surgery were 
initiated in the late 1980s — the early 1990s [12–15], 
researchers have been faced with a dual task of as-
sessing and improving HIPEC prophylactic efficacy, 
and simultaneously, of striving to maintain toxicities at 
a tolerable level. Both of these tasks have been tackled 
with a varying degree of success by experimenting with 
the choice, dosage and delivery of chemotherapy drugs. 
According to some researchers, most of the cases of 
HIPEC-related nephro- and hepatotoxicity were caused 
by cisplatin [8, 16, 17]. For example, Farma et al. (2005) 
[8] observed hematological toxicity in 27.8% of patients 
and impaired kidney function in 16.7% of patients at a cis-
platin dosage of 150–300 mg/m2. Kusamura et al. (2006) 
[17] showed that the administration of cisplatin at a dose 
of ≥ 240 mg/m2 was associated with a high risk of grade 
III–IV complications according to the WHO criteria. Juan 
et al. (2018) [10] reported that the platinum-based HIPEC 
regimen was fraught with a heightened risk of kidney func-
tion impairment — RR 3.04 (95% CJ 1.71–5.39), p < 0.001. 
According to some reports, the use of cisplatin in combi-
nation with mitomycin C caused hematological toxicity in 
2.5–5.3% of cases [7, 9]. In particular, it was reported that the 
use of only cisplatin at 1 mg/kg or of cisplatin at 0.5 mg/kg in 
combination with mitomycin C at 0.7 mg/kg resulted in grade 
III–IV hematological toxicity in 4.6% of cases and nephro-
toxicity — in 1.3% of cases [7]. When using a combination 
of cisplatin at 25 mg/m2/L + mitomycin C at 3.3. mg/m2/L or 
cisplatin at 43 mg/L + doxorubicin 15.25 mg/L, Kusamura et 
al. (2007) [9] observed grade III–IV hematological toxicity 
in 5.3% of cases and nephrotoxicity in 5.7% of cases. 
Proceeding from this information, we decreased the 
dosage of cisplatin to 50 mg/m2. We also took note of 
the research data emphasizing the need for a combined 
application of cisplatin with other chemotherapy drugs 
to ensure long-term GC treatment improvements com-
pared with treatment outcomes based on cisplatin-only 
intraperitoneal chemotherapy [5, 18–20]. Analyzing 
three cisplatin-only HIPEC efficacy trials [18–20], 
Feingold et al. noted in their meta-analysis (2017) [5] 
that the RR of the 5-year mortality was 0.79 (95% CI 
0.60–1.04; p = 0.09) with 2 of these studies (including 
one conducted in Europe [18]) failing to produce any 
statistically significant reduction in 5-year mortality. 
Taking into account the data on the ways of improv-
ing HIPEC efficacy available prior to the start of our trial 
we opted in favor of combining cisplatin with doxoru-
bicin as one of the most effective cytostatic drugs in GC 
treatment, yet proven safe in intraperitoneal application 
as was reported by Sugarbaker et al. (2005) [21]. Our 
choice of cisplatin/doxorubicin combination was also 
prompted by their multidirectional cancer-killing po-
tential thereby producing a synergic cancericidal effect. 
Proceeding from the published research data about the 
relatively low level of doxorubicin-related toxicities [21], 
we raised its dosage to 50 mg/m2 to add to the anti-cancer 
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potential of cisplatin whose dosage was lowered in our 
study on account of its comparatively high toxicity. 
Despite the increase in the doxorubicin dosage to 
50 mg/m2 exceeding that in similar studies, for example, 
a doxorubicin dose escalation study by Sugarbaker [22], 
no clinical manifestation of peritoneal adhesions was ob-
served during the follow-up monitoring period. Nor were 
there any pronounced adhesion processes or intestinal 
fibrosis registered during second-look laparoscopy. This 
outcome could possibly be attributed to a larger than 
usual volume of perfusate used in our study (5–6 L). 
Viewed overall, the above discussed dosage combi-
nation of cisplatin and doxorubicin proved to be effective 
both in terms of ensuring adequate patient tolerability 
and achieving good prophylactic efficacy outcomes of 
the proposed HIPEC regimen. 
A serious downside of the present study was the 
absence of systemic chemotherapy in the management 
of radically operated GC patients that is accounted 
for by the fact that at the time of launching the trial in 
2008 there was no universal standard of applying perio-
perative chemotherapy in the GC treatment. 
As if to highlight this drawback, the results of our study 
amply showed a need for supplementing adjuvant HIPEC 
with systemic chemotherapy in view of an increased risk 
of distant metastases [b = 0.2; RR 7.5 (95% CI 2.2–25) 
p < 0.001] against the backdrop of a reduced risk of devel-
oping metachronous peritoneal metastases [b = –1.60; RR 
0.2 (95% CI 0.11-0.37), p < 0.001] [2]. In our subsequent 
study combining HIPEC (cisplatin 50 mg/m2 and doxorubicin 
50 mg/m2) and 8 cycles of systemic chemotherapy (capecit-
abine + oxaliplatin or tegafur + oxaliplatin) we managed 
to improve long-term treatment outcomes by reducing the 
frequency and cumulative incidence of both metachronous 
peritoneal and distant metastases while achieving an ad-
equate patient tolerance to the combined application of 
HIPEC and adjuvant systemic chemotherapy [23, 24]. 
Furthermore, the low toxicity levels of the proposed 
HIPEC regimen (cisplatin 50 mg/m2 and doxorubicin 
50 mg/m2) demonstrated in our study give grounds to 
hypothesize the possibility of combining this HIPEC 
regimen not only with postoperative chemotherapy 
but also with chemotherapy administered periopera-
tively. Such a treatment strategy seems to be especially 
promising for managing patients exposed to a high risk 
of developing peritoneal dissemination, for example, 
patients with grade pT4b cancer. Obviously, further 
studies are needed to explore this possibility. 
Conclusions
While substantially improving long-term GC the- 
rapeutic effect, the proposed HIPEC regimen using 
cisplatin 50 mg/m2 in combination with doxorubicin 
50 mg/m2 made it possible to achieve satisfactory patient 
tolerability results both in terms of complications (fre-
quency of 26.3%) and toxicity (the frequency of grade 
I–III toxic reactions was 9.2% according to CTCAE, 
version 5.0). 
However, it is obvious that despite a growing number 
of positive reports on using adjuvant HIPEC for the 
treatment of gastric cancer associated with a high risk of 
implantation metastasis it is in many cases a ‘hit-or-miss’ 
process which means that we are still a long way off from 
developing definitive evidence-based recommendations 
and guidelines on the most effective HIPEC procedural 
techniques and combinations of chemotherapy agents to 
offer to clinicians, and likewise, from proposing optimal 
systemic chemotherapy regimens to be used in combi-
nation with HIPEC, a goal that can only be attained 
by conducting further studies in this field of research. 
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